ArticleJPRAS open2026
Ideal Sized Chitosan (Arche) as a multifunctional biomaterial in aesthetic treatment.
Article in JPRAS open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Aesthetic procedures such as laser resurfacing, microneedling, and injectable treatments intentionally disrupt the skin barrier, increasing susceptibility to microbial colonization, inflammation, and delayed healing. Post-procedural care therefore requires biomaterials that provide antimicrobial protection while supporting controlled inflammation and tissue regeneration. Observation: Chitosan, a naturally derived polysaccharide, exhibits a unique combination of antimicrobial activity, immunomodulatory effects, and wound-healing support. These properties are influenced by molecular weight, degree of deacetylation, and formulation, allowing chitosan to function as a barrier material, bioactive dressing, and drug-delivery platform in aesthetic settings. Due to its ultra-low molecular weight (below 600 Da), Ideal Size Chitosan (ISC) manufactured by Arche (Doum Inc., Korea) is topically effective, as it can penetrate the skin barrier to target deeper dermal layers and deliver enhanced bioactive effects. Clinical relevance: In post-aesthetic care, chitosan-based films, hydrogels, and nanoparticles may reduce infection risk, modulate excessive inflammatory responses, and promote re-epithelialization. However, variability among chitosan formulations and limited procedure-specific clinical data remain important considerations. Conclusion: This short communication highlights the rationale for using chitosan as a multifunctional biomaterial in aesthetic aftercare and underscores the need for standardized formulations and targeted clinical studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.